vida: extract claims from 2026-04-xx-nih-jama-psychiatry-glp1-cbt-alcohol-use-disorder-rct

- Source: inbox/queue/2026-04-xx-nih-jama-psychiatry-glp1-cbt-alcohol-use-disorder-rct.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -13,7 +13,7 @@ related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category
 supports: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients"]
 reweave_edges: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|supports|2026-04-14", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14"]
 sourced_from: ["inbox/archive/health/2026-04-13-kff-glp1-access-inversion-by-state-income.md"]
-related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access"]
+related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level"]
 ---
 
 # GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
@@ -46,3 +46,10 @@ Among patients with diagnosed conditions showing clear clinical benefit, uptake
 **Source:** HR Brew December 2025, 9amHealth partnership announcements
 
 The utilization vs. coverage divergence is now quantified: GLP-1 usage among surveyed populations (likely employer benefits) has 'more than doubled since 2023, reaching 49%' while total covered lives declined 22% (3.6M → 2.8M). This creates a dual-track access system where those who maintain coverage show dramatically higher utilization, while total population-level access worsens. The 9amHealth No-Barriers Bundle integrates medications from both Eli Lilly and Novo Nordisk at fixed monthly costs, but is only in discussions with employer groups as of early 2026 with no disclosed enrollment.
+
+
+## Supporting Evidence
+
+**Source:** JMCP 2026 Medicaid persistence study
+
+Medicaid population data shows 60.8% 6-month persistence with cost as primary discontinuation driver. This is the lowest-income, highest-chronic-disease-burden population, confirming that those who most need GLP-1 face the greatest structural barriers to sustained access. The cost barrier operates at the point of continuation, not just initial access.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -60,3 +60,10 @@ Qeadan et al. (2025) retrospective cohort study of 1.3M patients across 136 US h
 **Source:** Grigson PS et al., Addiction Science & Clinical Practice 2025
 
 NCT06548490 is the first Phase 2 RCT testing semaglutide for treatment-refractory OUD (n=200, patients already on buprenorphine/methadone who continue illicit use). Trial enrolled first participant January 2025, expected completion November 2026. Protocol formally published in Addiction Science & Clinical Practice (May 2025, PMID 40502777). This represents the definitive human trial that will either confirm or refute the animal/observational signal for OUD, extending the mechanism from AUD to opioid use disorders.
+
+
+## Supporting Evidence
+
+**Source:** Hendershot et al., JAMA Psychiatry 2025
+
+First RCT evidence: 26-week trial of 108 AUD+obesity patients showed semaglutide+CBT reduced heavy drinking days 41.1%, with NNT 4.3 versus 7+ for approved AUD medications. Blood-alcohol biomarkers corroborated self-reports. However, a separate cohort study found 195% increased MDD risk with GLP-1 agonists, requiring psychiatric screening.

domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: "Semaglutide plus CBT reduced heavy drinking days 41.1% in RCT, achieving NNT 4.3 versus 7+ for naltrexone and acamprosate, but limited to AUD patients with obesity comorbidity"
+confidence: experimental
+source: Hendershot et al., JAMA Psychiatry 2025; NIH press release April 2026
+created: 2026-05-02
+title: GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
+agent: vida
+sourced_from: health/2026-04-xx-nih-jama-psychiatry-glp1-cbt-alcohol-use-disorder-rct.md
+scope: causal
+sourcer: NIH / JAMA Psychiatry
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+challenges: ["the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"]
+---
+
+# GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
+
+A 26-week randomized, double-blind, placebo-controlled trial of 108 patients with both alcohol use disorder and obesity found that weekly semaglutide plus standard cognitive behavioral therapy produced a 41.1% reduction in heavy drinking days, with 13.7% greater improvement than placebo. The number needed to treat (NNT) was 4.3 — meaning approximately 4-5 patients need treatment to prevent one heavy drinking day. This represents a substantial improvement over approved AUD medications: naltrexone and acamprosate have NNTs of 7 or higher. Blood-alcohol biomarkers corroborated self-reported data, addressing a common validity concern in addiction research. The mechanism is hypothesized to involve GLP-1 receptor modulation of mesolimbic dopamine pathways, reducing the hedonic value of alcohol similar to how it reduces food craving. However, this finding is limited to the studied population: adults with comorbid AUD and obesity, which represents approximately 40% of AUD patients. A separate community-based cohort study found 195% increased risk of major depressive disorder among individuals treated with liraglutide or semaglutide, though this observational finding may be confounded by indication (obese/metabolically ill patients have higher baseline depression rates). Phase 3 trials are now underway to determine whether this efficacy translates to broader AUD populations and whether the depression risk signal is causal.

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -6,7 +6,7 @@ confidence: experimental
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
 related_claims: ["divergence-glp1-economics-chronic-cost-vs-low-persistence"]
-related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap"]
 reweave_edges: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints|related|2026-03-31", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling|related|2026-03-31", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04", "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|related|2026-04-17"]
 supports: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs"]
 sourced_from: ["inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md"]
@@ -88,3 +88,10 @@ Truveta ISPOR 2025 data confirms income >$80,000 predicts lower discontinuation
 **Source:** JAMA Network Open 2025 (PMC11786232)
 
 Income >$80K predicts lower discontinuation rates in this JAMA study, providing direct evidence that financial access barriers affect not just initiation but persistence. The income gradient operates throughout the treatment lifecycle, not just at the prescription decision point.
+
+
+## Supporting Evidence
+
+**Source:** JMCP 2026 Medicaid persistence study
+
+JMCP 2026 Medicaid study directly documents that cost is the #1 discontinuation driver, accounting for nearly half of discontinuations. This moves the claim from 'suggesting affordability' to 'proving affordability' as the binding constraint. The study explicitly measured discontinuation reasons rather than inferring from income correlations.

domains/health/mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-04-14-mhpaea-three-level-access-problem-synthesis.md
 scope: structural
 sourcer: Vida (synthesis)
 supports: ["mental-health-reimbursement-27pct-gap-structural-access-barrier"]
-related: ["SDOH-interventions-show-strong-roi-but-adoption-stalls-because-z-code-documentation-remains-below-3-percent-and-no-operational-infrastructure-connects-screening-to-action", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "mental-health-reimbursement-27pct-gap-structural-access-barrier", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance"]
+related: ["SDOH-interventions-show-strong-roi-but-adoption-stalls-because-z-code-documentation-remains-below-3-percent-and-no-operational-infrastructure-connects-screening-to-action", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "mental-health-reimbursement-27pct-gap-structural-access-barrier", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance", "mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement", "colorado-hb25-1002-establishes-outcomes-data-testing-authority-for-behavioral-health-parity-enforcement"]
 ---
 
 # MHPAEA enforcement has evolved to three levels — coverage design (level 1), access metrics (level 1.5, emerging 2025-2026), and reimbursement rate parity (level 2, not yet addressable) — with the paused 2024 Final Rule representing the first attempt to connect level 1.5 measurement to level 2 remediation
 
 MHPAEA enforcement has historically operated at Level 1 (coverage design parity): ensuring mental health benefits exist with comparable terms to medical/surgical benefits through NQTL analysis. Traditional enforcement actions like Georgia's $25M fine and Washington state fines all operate at this level. However, 2025-2026 saw the emergence of Level 1.5 (access metric enforcement): the DOL Kaiser settlement (Feb 2026) required reducing appointment wait times and monitoring network adequacy; Colorado HB 25-1002 requires documented access timelines and outcomes data testing; Illinois is enforcing the full 2024 Final Rule including outcome data evaluation. The Mental Health Parity Index (April 2026) provides the first national tool for measuring access disparities at state/county level using reimbursement benchmarks. But Level 2 (reimbursement rate parity) remains unaddressed: the 27.1% mental health provider reimbursement gap vs. medical/surgical (RTI International/Kennedy Forum 2024) is the mechanism that drives narrow networks and access failures. The 4th MHPAEA Report documented payers actively raising M/S reimbursement to fix network gaps while NOT applying the same methodology to MH networks. The structural trap: MHPAEA can require comparable coverage design and is developing tools to measure access outcomes, but enforcement stops at requiring insurers to fix level 1.5 failures without identifying the level 2 mechanism. The paused 2024 rule's outcome data evaluation requirement would have connected level 1.5 measurement to level 2 causation by requiring insurers to identify and fix underlying causes when outcome data shows persistent access gaps despite NQTL compliance. Illinois and Colorado represent natural experiments testing whether outcome data evaluation changes insurer reimbursement behavior, with results observable in 2-3 years.
+
+
+## Extending Evidence
+
+**Source:** Kennedy Forum / NY Community Trust / NY DFS, April 2026
+
+New York becomes the second state after Illinois to commit to deep-dive parity analysis using the Mental Health Parity Index for level 2 (reimbursement rate) evidence. The transparent payer file data architecture is specifically designed to enable state-level enforcement without federal cooperation. If NY DFS finds systematic reimbursement parity violations, enforcement actions would likely exceed Georgia's $25M record given the 11M commercially insured population and NY DFS's aggressive enforcement track record.

domains/health/semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x.md

@@ -5,16 +5,9 @@ description: "Within the GLP-1 class, semaglutide shows 2.5x better one-year per
 confidence: likely
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
-related:
-- semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
-reweave_edges:
-- semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings|related|2026-04-04
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|related|2026-04-09
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09
-sourced_from:
-- inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md
+related: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings", "GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism"]
+reweave_edges: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings|related|2026-04-04", "GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|related|2026-04-09", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09"]
+sourced_from: ["inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md"]
 ---
 
 # Semaglutide achieves 47 percent one-year persistence versus 19 percent for liraglutide showing drug-specific adherence variation of 2.5x
@@ -47,4 +40,10 @@ Relevant Notes:
 - [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
 
 Topics:
-- domains/health/_map
+- domains/health/_map
+
+## Extending Evidence
+
+**Source:** JMCP 2026 Medicaid study
+
+Tirzepatide shows 71.7% 6-month persistence vs semaglutide 56.5% in Medicaid population — a 15 percentage point gap. This is larger than the previously documented semaglutide-liraglutide gap and occurs in the most cost-constrained population, suggesting the persistence advantage may be driven by superior tolerability/efficacy rather than selection bias alone. However, 6-month data only — 12-month durability unknown.

inbox/archive/health/2026-04-30-ny-state-mental-health-parity-index-11m-commercially-insured.md

@@ -7,10 +7,13 @@ date: 2026-04-30
 domain: health
 secondary_domains: []
 format: news-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: medium
 tags: [mental-health, parity, MHPAEA, New-York, DFS, state-enforcement, Kennedy-Forum]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-xx-jmcp-glp1-medicaid-persistence-tirzepatide-vs-semaglutide.md

@@ -7,10 +7,13 @@ date: 2026-03-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: medium
 tags: [GLP-1, Medicaid, persistence, adherence, semaglutide, tirzepatide, real-world-evidence, cost-barriers]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-xx-nih-jama-psychiatry-glp1-cbt-alcohol-use-disorder-rct.md

@@ -7,10 +7,13 @@ date: 2026-04-01
 domain: health
 secondary_domains: []
 format: research-summary
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: high
 tags: [GLP-1, semaglutide, alcohol-use-disorder, behavioral-health, mental-health, clinical-trial, RCT]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content